Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9

Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study

Authors Jeong JH, Bahk WM, Woo YS, Seo HJ, Hong SC, Jon DI, Min KJ, Yoon BH

Received 3 December 2012

Accepted for publication 8 January 2013

Published 8 February 2013 Volume 2013:9 Pages 197—204

DOI https://doi.org/10.2147/NDT.S41081

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Jong-Hyun Jeong,1 Won-Myong Bahk,1 Young Sup Woo,1 Ho-Jun Seo,1 Seung-Chul Hong,1 Duk-In Jon,2 Kyung Joon Min,3 Bo-Hyun Yoon4

1Department of Psychiatry, College of Medicine, The Catholic of University of Korea, Seoul, 2Department of Psychiatry, College of Medicine, Hallym University, Anyang, 3Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul, 4Naju National Hospital, Naju, Korea

Purpose: To evaluate and compare the therapeutic efficacy of quetiapine in bipolar I and II depression patients in the clinical setting.
Patients and methods: This was an 8-week, multicenter, open-label, observational study for bipolar depression. The dosage of quetiapine was flexible, and concomitant medications were permitted on clinician's judgments. A total of 1097 patients were enrolled, and 764 bipolar depression patients who exhibited good therapeutic compliance (>75% compliance rate) were analyzed.
Results: Clinical Global Impression – Bipolar scale and Montgomery–Asberg Depression Rating Scale scores were significantly improved at weeks four and eight compared with the baseline scores. At the end of the 8-week study, the response rate was 58.9%, and the remission rate was 42.1%. However, there were no significant differences in the response and remission rates between bipolar I and II disorder (BD-I and BD-II) patients (response rate 60.1% versus 56.3%; remission rate 44.5% versus 37.0%). Montgomery–Asberg Depression Rating Scale score at baseline (β = 0.612, P < 0.001), duration of current episode (β = −0.152, P = 0.001), and presence of remission on previous episode (β = 0.111, P = 0.012) were significantly associated with improvements in depressive symptoms. Fatigue (16.0%), somnolence (14.9%), and manic/hypomanic switching (0.6% at week four, 0.3% at week eight) were observed throughout the study period.
Conclusion: The results of this study suggest that quetiapine improves depressive symptoms in BD-I and BD-II patients with a minimal incidence of manic switching. The therapeutic efficacy of quetiapine increased with time. Quetiapine could be an effective and safe modality for the treatment of BD-I and BD-II.

Keywords: bipolar depression, quetiapine, therapeutic efficacy, observational study

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines

Jeong JH, Lee JG, Kim MD, Sohn IK, Shim SH, Wang HR, Woo YS, Jon DI, Seo JS, Shin YC, Min KJ, Yoon BH, Bahk WM

Neuropsychiatric Disease and Treatment 2015, 11:1561-1571

Published Date: 26 June 2015

Sleep and cognitive problems in patients with attention-deficit hyperactivity disorder

Lee HK, Jeong JH, Kim NY, Park MH, Kim TW, Seo HJ, Lim HK, Hong SC, Han JH

Neuropsychiatric Disease and Treatment 2014, 10:1799-1805

Published Date: 17 September 2014

A case report of suicidal behavior related to subclinical hyperthyroidism

Joo SH, Jeong JH, Hong SC

Neuropsychiatric Disease and Treatment 2014, 10:641-643

Published Date: 17 April 2014

Olanzapine use in a manic patient during second and third trimester pregnancy

Choi L, Joo SH, Jeong JH

Neuropsychiatric Disease and Treatment 2014, 10:325-328

Published Date: 17 February 2014

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010